Prognosticating Survival in Hepatocellular Carcinoma with Elevated Baseline Alpha-fetoprotein Treated with Radioembolization Using a Novel Laboratory Scoring System: Initial Development and Validation.


Journal

Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538

Informations de publication

Date de publication:
May 2019
Historique:
received: 03 11 2018
accepted: 21 02 2019
pubmed: 3 3 2019
medline: 6 6 2019
entrez: 3 3 2019
Statut: ppublish

Résumé

To investigate laboratory parameters as predictors of overall survival (OS) for hepatocellular carcinoma (HCC) treated with radioembolization and develop/validate a scoring system. With IRB approval, we included all patients with baseline alpha-fetoprotein (AFP) > 100 ng/dL from our prospectively acquired HCC radioembolization database. Neutrophil-lymphocyte ratio, albumin-bilirubin (ALBI), and AFP were measured at baseline and at 1-, 3-, and 6-month post-radioembolization Landmarks. OS was assessed from these Landmarks. Univariate/multivariate analyses were performed to evaluate OS predictability of these parameters. Baseline Imaging, Laboratory, and Combination scoring systems were developed. Developing/validating groups were created to investigate/validate the score's OS predictability. Time-dependent receiver operating characteristics (ROC) were evaluated. Patients were stratified into groups I, II, and III by using 25th and 75th percentile cutoffs according to change in Laboratory Score from baseline. 345/401 (86%), 238/401 (59%), and 167/401 (42%) patients had laboratory parameters available at the 1-, 3-, and 6-month Landmarks, respectively. ALBI and AFP were significant OS prognosticators at all Landmarks. The Laboratory Score [ALBI + (0.3 × LnAFP)] was developed/internally validated to predict OS from these Landmarks. Areas under the curve of time-dependent ROCs of the Baseline Imaging vs. Laboratory scores in predicting patient OS post 3 and 6 months Landmarks were 0.56 versus 0.82 and 0.57 versus 0.77, respectively. OS differences in groups I, II, and III according to change in Laboratory Score from baseline were significant (p < 0.001). Post-radioembolization AFP and ALBI scores were significant OS prognosticators. A decrease in post-therapeutic Laboratory Score, which combines AFP and ALBI, correlates with an improved OS.

Identifiants

pubmed: 30824946
doi: 10.1007/s00270-019-02191-z
pii: 10.1007/s00270-019-02191-z
doi:

Substances chimiques

alpha-Fetoproteins 0

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

700-711

Commentaires et corrections

Type : ErratumIn

Auteurs

Rehan Ali (R)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Yihe Yang (Y)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Mark Antkowiak (M)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Ahmed Gabr (A)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Ronald Mora (R)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Nadine Abouchaleh (N)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Ali Al Asadi (A)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Laura Kulik (L)

Division of Hepatology, Department of Medicine, Northwestern University, Chicago, IL, USA.

Daniel Ganger (D)

Division of Hepatology, Department of Medicine, Northwestern University, Chicago, IL, USA.

Michael Abecassis (M)

Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, IL, USA.

Nitin Kataraya (N)

Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, IL, USA.

Mary Mulcahy (M)

Division of Oncology, Department of Medicine, Northwestern University, Chicago, IL, USA.

Al Benson (A)

Division of Oncology, Department of Medicine, Northwestern University, Chicago, IL, USA.

Devalingam Mahalingam (D)

Division of Oncology, Department of Medicine, Northwestern University, Chicago, IL, USA.

Bartley Thornburg (B)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Samdeep Mouli (S)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Robert J Lewandowski (RJ)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.
Division of Hepatology, Department of Medicine, Northwestern University, Chicago, IL, USA.

Riad Salem (R)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.
Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, IL, USA.
Division of Hepatology, Department of Medicine, Northwestern University, Chicago, IL, USA.

Ahsun Riaz (A)

Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA. ahsun-riaz@northwestern.edu.
Feinberg School of Medicine, Northwestern University, 676 N. St. Clair, Suite 800, Chicago, IL, 60611, USA. ahsun-riaz@northwestern.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH